Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab ... Trial groups (ENGOT), and NRG Oncology-Japan. Patients were of a median age of 51 years old ...

THIO (6-thio-2′-deoxyguanosine), an investigational telomere-targeting agent sequenced in combination with Regeneron’s Libtayo (cemiplimab), a programmed cell death protein 1 (PD-1 ...

Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen increasingly throughout 2024. | Revenues in the biopharma industry continued to boom ...

Regeneron Pharmaceuticals ... In addition, the company’s cancer medicine Libtayo brought in $289 million in sales in fiscal Q3 2024, up 24% compared to the year-ago period.

THIO (6-thio-2′-deoxyguanosine), an investigational telomere-targeting agent sequenced in combination with Regeneron’s Libtayo (cemiplimab), a programmed cell death protein 1 (PD-1) inhibitor. Libtayo ...

In a surprise announcement, Regeneron began a dividend at $0.88/share. A ~$4.5B share repurchase program adds further value. LIBTAYO demonstrated massive growth, accelerating to 50% in Q4 2024 ...

After its approval in 2018, Libtayo made solid annual sales gains from $348 million in 2020 to $578 million two years later. In 2022, Regeneron paid its partner Sanofi $900 million for full rights ...

Currently, the flagship of Regeneron's oncology franchise is Libtayo (cemiplimab-rwlc), which is an anti-PD-1 monoclonal antibody that is approved for the treatment of several types of cancer.

Regeneron is a global leader in cancer research and development, and the combination of IMM-1-104 and Libtayo in advanced non-small cell lung cancer has the potential to address unmet needs for ...

Down 50% With a 5.9% Dividend Yield, Here's Why This Dirt Cheap Value Stock Is Worth Buying in February Want to Make More Passive Income? These 2 Dividend Stocks Offer Yields Above 6%. Want ...